GUARDANT HEALTH, INC. vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Veracyte's balance sheet holds a 9.3 current ratio with no debt and, unlike most of its cohort, an income statement that has finished the crossing: a 16.3% operating margin netting 16.3%, priced at 56 times earnings. Guardant holds a 4.7 current ratio being spent, a negative 40.2% operating margin, and no multiple, at four times Veracyte's market value, $20B against $5B. Both develop advanced diagnostics; only one has proven the economics. The market pays quadruple for the unproven one because its addressable market, blood-based screening for many cancers, dwarfs Veracyte's thyroid-and-lung niches. Scale of ambition against proof of concept: the valuation gap is the price of the dream net of the evidence.
Comparison updated 2026-07-10.
| Metric | GH | VCYT |
|---|---|---|
| Price | $149.32 | $60.46 |
| Market cap | $19.6B | $4.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | — | 56.0 |
| P/B | — | 3.66 |
| P/S | 18.15 | 9.07 |
| EV/EBITDA | — | 56.1 |
| Revenue growth | +39.3% | +16.9% |
| Gross margin | — | 72.7% |
| Operating margin | -40.2% | 16.3% |
| Net margin | -40.1% | 16.3% |
| Return on equity | — | 6.5% |
| Return on assets | -22.6% | 6.1% |
| Return on invested capital | -26.7% | 5.5% |
| FCF yield | -1.2% | 3.2% |
| Debt / equity | — | 0.00 |
| Current ratio | 4.68 | 9.31 |
| Altman Z (solvency) | 4.37 | 6.48 |
| Piotroski F (quality) | 3 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.